Emyria has received ethics approval for our pivotal Phase 3 clinical trial of EMD-RX5!

We're now one step closer to registering our first Ultra-Pure CBD capsule as an over-the-counter treatment with the TGA.

All necessary safety and efficacy evaluations of EMD-RX5 are complete, and Emyria will now commence recruitment with Clinitrials, supported by Emyria’s clinical service subsidiary, Emerald Clinics.

I spoke to Proactive about this huge milestone and the progress we've made in the last 12 months. You can watch the full interview with Proactive here. 

So much more to come!

Follow our progress here in our new interactive Investor Hub. We welcome you to ask direct questions and discuss all of our announcements.

Kind regards,

Michael Winlo

Emyria MD, CEO